Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Mesoblast (MSB) has received U.S. Food and Drug Administration (FDA) clearance to treat COVID-19 patients with its remestemcel-L product
  • In particular, remestemcel-L will be used to treat patients with acute respiratory distress syndrome which is the most common cause of death relating to COVID-19
  • This product has already proven effective in improving lung function in similar conditions
  • Recent clinical trials showed remestemcel-L to either completely cure or significantly improve functional outcomes for all patients
  • Mesoblast has spiked 30.5 per cent on the market this morning and shares are trading for $1.76 each

Mesoblast (MSB) has received U.S. Food and Drug Administration (FDA) clearance to treat COVID-19 patients with its remestemcel-L product.

In particular, it will be used to treat acute respiratory distress syndrome (ARDS) which is common in patients with COVID-19.

“The FDA clearance provides a pathway in the United States for use of remestemcel-L in patients with COVID-19 ARDS, where the prognosis is very dismal, under both expanded access compassionate use and in a planned randomised controlled trial,” Chief Medical Officer Dr Fred Grossman commented.

Remestemcel-L is an investigational therapy that is made up of mesenchymal stem cells (cells that come from different parts of the body) that are taken from an unrelated donor.

In a recent clinical trial that tested the stem cells against COVID-19 related pneumonia, the treatment was shown to either completely cure or significantly improve functional outcomes for all patients.

Additionally, remestemcel-L has been proven to significantly enhance lung function in patients with chronic obstructive pulmonary disease (COPD), a group of lung diseases that make it difficult to breathe.

Given the similarities between COPD and ARDS caused by COVID-19, Mesoblast has made the connection that remestemcel-L is likely to have a similar outcome on patients with COVID-19 as it did those with COPD.

Originally, remestemcel-L was used to treat steroid-refractory acute versus host. disease, a condition in which the body rejects bone marrow transplants.

This product is now available in Japan under the name Temcell.

Mesoblast has spiked 30.5 per cent on the market this morning and shares are trading for $1.76 each at 10:53 am AEST.

MSB by the numbers
More From The Market Herald
Dimerix (ASX:DXB) - Managing Director and CEO, Nina Webster

" Dimerix (ASX:DXB) expands DMX-200 study into Australia

Dimerix (DXB) has entered an agreement with the NHMRC Clinical Trials Centre at the University of Sydney to expand the CLARITY 2.

" ACCC scrambles to halt Virtus Health’s (ASX:VRT) purchase of Healius (ASX:HLS) IVF clinics

The ACCC has taken “a significant step” as it seeks an urgent injunction to stop Virtus Health’s (VRT) proposed acquisition of Adora Fertility
IDT Australia (ASX:IDT) - Chair, Alan Fisher

" IDT Australia (ASX:IDT) signs manufacturing deal with Monash University

IDT Australia (IDT) has entered a master services agreement and services order with Monash University.
Prescient Therapeutics (PTX) - CEO and MD, Steven Yatomi Clarke

" Prescient Therapeutics (ASX:PTX) to present new OmniCAR data at conference

Prescient Therapeutics (PTX) will present new results for its OmniCAR drug at the Cell & Gene Meeting on Mesa in California.